Cheat sheet
SPLE (Pharmacist) Cheat Sheet
Basic Biomedical Sciences
- 10% of exam
- Physiology Biochemistry & Enzymology Microbiology & Immunology Molecular Genetics Pharmacogenomics Basics
Pharmaceutical Sciences
- 35% of exam
- Pharmacology & Toxicology Pharmacokinetics & ADME Medicinal Chemistry Pharmaceutical Calculations Sterile & Nonsterile Compounding Pharmacognosy
Social/Behavioral/Admin Sciences
- 20% of exam
- Saudi Pharmacy Law SFDA Regulation Pharmacovigilance Pharmacoeconomics Pharmacy Management Biostatistics & Ethics
Clinical Sciences
- 35% of exam
- Cardiovascular Therapeutics Endocrine Therapeutics Infectious Disease Therapeutics Respiratory Therapeutics Clinical PK & TDM Special Populations
Quick Facts
- Exam SPLE (Pharmacist)
- Owner SCFHS
- Delivery Prometric CBT
- Format 200 scored MCQs, two parts
- Time 4h30m, one 30-min break
- Passing score 536 on 200-800 scale
- Question types Recall plus scenario-based
- Eligibility SCFHS classification via Mumaris+
Competitive vs Noncompetitive Inhibition BA
Competitive
- Raises apparent Km
- Vmax unchanged
Noncompetitive
- Km unchanged
- Lowers Vmax
- More substrate overcomes competitive inhibition only
Physiology & Biochem BA
- Frank-Starling law Preload raises stroke volume
- Km Substrate conc at half Vmax
- Vmax Max rate, saturated enzyme
- Competitive inhibitor Raises Km, same Vmax
- Noncompetitive inhibitor Lowers Vmax, same Km
- Beta-1 stimulation Raises heart rate, contractility
Gram-Positive vs Gram-Negative BA
Gram-Positive
- Thick peptidoglycan wall
- Stains purple
Gram-Negative
- Outer membrane with LPS
- Stains pink
- LPS lipid A causes septic shock
Microbio, Immuno & Genetics BA
- Gram-positive wall Thick peptidoglycan, retains violet
- Gram-negative wall Outer membrane, LPS endotoxin
- Lipid A Endotoxin causing septic shock
- Type I reaction IgE-mediated, immediate anaphylaxis
- Type IV reaction T-cell mediated, delayed onset
- CYP2D6 poor metabolizer Low codeine to morphine conversion
Warfarin Blocks 1972 PH
- Warfarin blocks clotting factors two, seven, nine, ten
- II VII IX X
Solution vs Suspension PH
Solution
- Fully dissolved
- Clear, no settling
Suspension
- Insoluble particles dispersed
- Shake before use
- Suspensions always need shaking first
Calculation Method Picker PH
- Pediatric weight-based dosing → Clark's Rule ( mg/kg often more accurate )
- Chemo or narrow-index dosing → Mosteller BSA formula ( Height and weight based )
- Manual IV drip rate → gtt/min formula ( Drop factor times volume )
- Dilute stock to lower strength → C1V1 equals C2V2 ( Solve for volume needed )
- Mix two different strengths → Alligation tic-tac-toe method ( Differences give mixing ratio )
- Adjust dose for renal impairment → Cockcroft-Gault CrCl estimate ( Weight, age, SCr, sex )
Pharmacology & Toxicology PH
- Naloxone Mu-receptor antagonist, opioid reversal
- NAPQI Toxic acetaminophen metabolite
- N-acetylcysteine Acetaminophen overdose antidote
- Warfarin target Inhibits VKORC1 enzyme
- COX-1 inhibition Raises GI bleeding risk
- COX-2 selective NSAID Raises cardiovascular thrombotic risk
Cockcroft-Gault Inputs PH
- Age, weight, sex, and serum creatinine estimate clearance
- Age Weight Sex SCr
Zero-Order vs First-Order Kinetics PH
Zero-Order
- Constant amount eliminated
- Rate independent of concentration
First-Order
- Constant fraction eliminated
- Rate proportional to concentration
- Most drugs follow first-order elimination kinetics
Pharmacokinetics & ADME PH
- Vd formula Dose over initial concentration
- High Vd example Digoxin, about 500 L
- Low Vd example Warfarin, about 8-10 L
- Bioavailability F Fraction reaching systemic circulation
- IV bioavailability 100% by definition
- Steady state 94% reached after 4 half-lives
Pharmaceutical Calculations PH
- C1V1 = C2V2 Dilution concentration-volume equation
- Alligation Mixing two strengths ratio
- Clark's Rule Weight over 150, times dose
- Mosteller BSA Height times weight, over 3600
- IV flow rate Volume times drop factor, over time
- Zero-order kinetics Constant amount eliminated per time
Pharmacy Practice & Compounding PH
- USP <797> Sterile compounding categories 1-3
- Category 3 CSP Up to 180-day beyond-use date
- Solution Fully dissolved, single phase
- Suspension Insoluble solids, shake before use
- Emulsion Two immiscible liquids, stabilized
- Bioequivalence Same rate and extent absorbed
Pharmacognosy & Natural Products PH
- St. John's Wort Induces CYP3A4 and P-gp
- Ginkgo biloba Antiplatelet, raises bleeding risk
- Digoxin source Foxglove (Digitalis) plant
- Herbal disclosure Ask before surgery, anticoagulants
- B12 malabsorption After gastrectomy or metformin use
SFDA vs SCFHS Roles SO
SFDA
- Regulates drugs and devices
- Runs pharmacovigilance (Tiyaqquz)
SCFHS
- Licenses healthcare practitioners
- Administers the SPLE exam
- SFDA regulates products, SCFHS regulates people
Which Saudi Authority SO
- Report serious adverse reaction → SFDA NPC via Tiyaqquz
- Register or schedule a drug → Saudi Food and Drug Authority
- License or classify a pharmacist → SCFHS through Mumaris+
- Free chronic disease medication → Wasfaty via NUPCO pharmacies
- Approve pharmacy formulary drug → P&T committee decision
- Require licensed pharmacy manager → SFDA responsible-manager rule
Saudi Pharmacy Law SO
- SFDA Regulates drugs, devices, cosmetics
- SCFHS Licenses practitioners, runs SPLE
- Mumaris+ SCFHS eligibility application platform
- Controlled schedules Saudi law, Schedules I-V
- Responsible manager Full-time licensed pharmacist required
- Wasfaty Free chronic medication e-prescribing
Pharmacovigilance & Pharmacoeconomics SO
- Pharmacovigilance Detects, assesses, prevents drug harm
- NPC SFDA's national ADR monitoring division
- Tiyaqquz SFDA's electronic ADR reporting system
- Cost-effectiveness analysis Cost per outcome, e.g. QALY
- QALY Quality-adjusted life year measure
- Formulary P&T committee's approved drug list
Management, Ethics & Biostats SO
- Informed consent Patient understands, agrees voluntarily
- Confidentiality Protect patient health information
- Cohort study Follows exposed group forward
- Case-control study Starts from outcome, looks back
- Relative risk Risk ratio between two groups
- CPOE Computerized order entry, reduces errors
RIPE for TB CL
- Rifampin, Isoniazid, Pyrazinamide, Ethambutol treat active tuberculosis
- Rifampin Isoniazid Pyrazinamide Ethambutol
Trough-Only vs AUC-Guided Vancomycin CL
Trough-Only (older)
- Target 15-20 mg/L
- Higher nephrotoxicity risk
AUC24-Guided (current)
- Target AUC 400-600
- Preferred for serious MRSA
- Use AUC24-guided dosing today
Empiric Therapy Picker CL
- Active drug-susceptible tuberculosis → RIPE regimen, 6 months ( 2mo intensive, 4mo continuation )
- Serious MRSA infection → Vancomycin, AUC24-guided dosing ( Target AUC24 400-600 )
- H. pylori peptic ulcer → Triple or quadruple therapy
- CAP with penicillin allergy → Macrolide or fluoroquinolone
- Azole plus CYP3A4 substrate → Adjust dose or avoid ( Statin, warfarin risk rises )
- Cultures and susceptibility return → De-escalate to narrow agent
Cardiovascular & Endocrine Therapy CL
- First-line hypertension ACEI/ARB, CCB, or thiazide
- BP target Below 130/80 mmHg, most adults
- HFrEF four pillars ACEI/ARB/ARNI, beta-blocker, MRA, SGLT2i
- Target INR 2.0 to 3.0, most indications
- Metformin limit Avoid below eGFR 30
- Levothyroxine Empty stomach, recheck TSH later
Four Pillars of HFrEF CL
- ACEI/ARB/ARNI, beta-blocker, MRA, and an SGLT2 inhibitor
- ACEI/ARB/ARNI Beta-blocker MRA SGLT2 inhibitor
Beta-1 Selective vs Nonselective CL
Beta-1 Selective
- Metoprolol, atenolol, bisoprolol
- Safer in asthma
Nonselective
- Propranolol, nadolol, timolol
- Avoid in asthma/COPD
- Choose selective agents for reactive airways
Infectious Disease & Respiratory CL
- RIPE regimen Rifampin, isoniazid, pyrazinamide, ethambutol
- TB duration 2-month intensive, 4-month continuation
- Empiric antibiotics Guided by site, local resistance
- De-escalation Narrow therapy after culture results
- Azole interaction Inhibits CYP3A4, raises statin levels
- GINA asthma ICS-formoterol preferred reliever, all steps
Clinical PK & TDM CL
- Vancomycin target AUC24 400-600 mg*h/L
- Old vancomycin trough 15-20 mg/L, serious infection
- Digoxin range 0.5-2.0 ng/mL, narrow index
- Digoxin toxicity sign Yellow-green visual halos
- Cockcroft-Gault Estimates creatinine clearance, bedside
- Hypokalemia Increases digoxin toxicity risk
Special Populations CL
- Pregnancy contraindication ACEI/ARB, warfarin, isotretinoin, valproate
- Breastfeeding analgesic Short-term paracetamol usually preferred
- Pediatric amoxicillin Weight-based mg/kg/day dosing
- Geriatric polypharmacy Anticholinergics raise fall risk
- CKD stage 4 Avoid standard adult NSAID dose
- CYP2C19 poor metabolizer Reduced clopidogrel activation
Common Traps
Digoxin Level Timing
- Draw level pre-dose only ≠ Not right after dosing
ACE Inhibitors in Pregnancy
- Contraindicated all trimesters ≠ Fetotoxic, especially later terms
SFDA vs SCFHS Confusion
- SFDA regulates products ≠ SCFHS licenses practitioners
Outdated Vancomycin Trough Target
- 15-20 mg/L is old ≠ AUC24 400-600 now preferred
Km vs Vmax Inhibition
- Competitive raises Km only ≠ Noncompetitive lowers Vmax only
Clark's Rule Limitations
- Rough weight-based estimate only ≠ BSA more accurate, narrow-index
COX-2 Selective NSAID Risk
- Spares GI, less bleeding ≠ Raises cardiovascular thrombotic risk
Last Minute
- 1. SPLE has 200 scored MCQs.
- 2. Exam splits into two 100-question parts.
- 3. Testing time totals 4h30m.
- 4. Passing score is 536 of 800.
- 5. Pharma & Clinical Sciences: 35% each.
- 6. Vancomycin targets AUC24 400-600 mg*h/L.
- 7. Target INR is 2.0 to 3.0.
- 8. TB regimen: RIPE for two months.
- 9. Cockcroft-Gault estimates creatinine clearance, bedside.
- 10. SFDA regulates drugs; SCFHS licenses pharmacists.
- 11. Wasfaty gives free chronic-disease medications.
- 12. USP <797> allows 180-day beyond-use dates.
- 13. ACE inhibitors are contraindicated in pregnancy.
Saudi Pharmacist Licensure Examination (SPLE - Pharmacist)
- Practice Questions 100 questions Study Guide 42 topics Cheat Sheet 83 facts Flashcards 50 cards Podcast